

TEXAS Diabetes Data & Forecasts

State Total Population Forecasts	2015	2020	2025	2030
Entire Population	26,585,800	28,634,900	30,865,100	33,317,700
Prediabetes	7,498,800	8,343,100	9,262,000	10,011,300
Diagnosed diabetes	2,244,800	2,863,800	3,470,500	4,045,100
Undiagnosed diabetes	796,300	964,800	1,109,300	1,225,000
Total with diabetes (diagnosed and undiagnosed)	3,041,000	3,828,600	4,579,800	5,270,100
Complications:				
Visual impairment	368,100	455,900	536,200	606,800
Renal failure	5,350	6,590	7,700	8,660
Leg amputations	4,650	5,440	6,070	6,510
Annual deaths attributable to diabetes	24,170	29,450	33,880	37,400
Total annual cost (2015 dollars)	\$27.7 B	\$34.6 B	\$41.3 B	\$47.6 B
Annual medical costs	\$20.9 B	\$26.0 B	\$31.0 B	\$35.6 B
Annual nonmedical costs	\$6.8 B	\$8.6 B	\$10.3 B	\$12.0 B

State Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	3,112,900	3,755,800	4,500,200	5,186,200
Prediabetes	1,587,600	1,915,500	2,295,100	2,645,000
Diagnosed diabetes	588,300	709,800	850,500	980,200
Undiagnosed diabetes	217,900	262,900	315,000	363,000
Total with diabetes (diagnosed and undiagnosed)	806,200	972,800	1,165,500	1,343,200
Complications:				
Visual impairment	110,100	129,300	151,100	169,600
Renal failure	1,810	2,110	2,450	2,730
Leg amputations	1,360	1,520	1,680	1,790
Annual deaths attributable to diabetes	16,680	19,730	22,020	23,560
Total annual cost (2015 dollars)	\$10.3 B	\$12.4 B	\$14.9 B	\$17.2 B
Annual medical costs	\$9.7 B	\$11.7 B	\$14.0 B	\$16.1 B
Annual nonmedical costs	\$0.6 B	\$0.7 B	\$0.9 B	\$1.1 B

These forecasts are based on the latest available national diabetes data, including U.S Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit www.altfutures.org/diabetes2030.

Research funded by Novo Nordisk Inc.